How to buy Vir Biotechnology shares | $33.43
Own Vir Biotechnology shares in just a few minutes.
Vir Biotechnology, Inc is a biotechnology business with stocks listed in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$33.43 – an increase of 4.44% over the previous week.
How to buy shares in Vir Biotechnology
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Vir Biotechnology. Find the share by name or ticker symbol: VIR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vir Biotechnology reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$33.43, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vir Biotechnology, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Vir Biotechnology. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted Vir Biotechnology's share price?
Since the stock market crash in March caused by coronavirus, Vir Biotechnology's share price has had significant positive movement.
Its last market close was US$33.43, which is 51.36% up on its pre-crash value of US$16.26 and 107.77% up on the lowest point reached during the March crash when the shares fell as low as US$16.09.
If you had bought US$1,000 worth of Vir Biotechnology shares at the start of February 2020, those shares would have been worth US$1,605.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$1,465.91.
Vir Biotechnology share priceUse our graph to track the performance of VIR stocks over time.
Vir Biotechnology shares at a glance
|Latest market close||USD$33.43|
|52-week range||USD$11.6504 - USD$75|
|50-day moving average||USD$42.1659|
|200-day moving average||USD$38.6869|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.76|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Vir Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vir Biotechnology price performance over time
|1 week (2020-09-13)||N/A|
|1 month (2020-08-24)||-22.17%|
|3 months (2020-06-20)||N/A|
|6 months (2020-03-23)||-8.69%|
|1 year (2019-09-20)||N/A|
|2 years (2018-09-20)||N/A|
|3 years (2017-09-20)||N/A|
|5 years (2015-09-20)||N/A|
Vir Biotechnology financials
|Revenue TTM||US$75.1 million|
|Gross profit TTM||US$-134,981,000|
|Return on assets TTM||-22.96%|
|Return on equity TTM||-45.69%|
|Market capitalisation||US$4.2 billion|
TTM: trailing 12 months
Shorting Vir Biotechnology shares
There are currently 4.3 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 52.3% up from 2.8 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR)
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 1.0 million). Vir Biotechnology's SIR currently stands at 4.14. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 4140 shares are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 30 shares are currently held short) or 0.0536% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 54 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vir Biotechnology.
Find out more about how you can short Vir Biotechnology stock.
Vir Biotechnology share dividends
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Vir Biotechnology overview
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Frequently asked questions
Ask an Expert